There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (NASDAQ:COLL) and Boston Scientific Corp (NYSE:BSX) with bullish sentiments.
Collegium Pharmaceutical (COLL)
Piper Jaffray analyst David Amsellem reiterated a Buy rating on Collegium Pharmaceutical yesterday and set a price target of $32. The company’s shares opened today at $18.20.
According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -0.9% and a 45.9% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Amphastar Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Collegium Pharmaceutical with a $31 average price target, which is a 70.3% upside from current levels. In a report issued on August 6, Janney Montgomery also maintained a Buy rating on the stock with a $27 price target.
.
See today’s analyst top recommended stocks >>
Boston Scientific Corp (BSX)
Piper Jaffray analyst Matthew O’Brien reiterated a Buy rating on Boston Scientific Corp yesterday and set a price target of $40. The company’s shares opened today at $34.22.
According to TipRanks.com, O’Brien is a top 100 analyst with an average return of 27.3% and a 70.3% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Merit Medical Systems, and Baxter International.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific Corp with a $37.75 average price target, which is a 10.3% upside from current levels. In a report issued on July 24, Cowen & Co. also reiterated a Buy rating on the stock with a $39 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
